Related Experiment Video

Updated: Jun 25, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

ErbB receptors and signaling pathways in cancer

Nancy E Hynes1, Gwen MacDonald

  • 1Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland. hynes@fmi.ch

Current Opinion in Cell Biology
|February 12, 2009
PubMed

Insights

ErbB receptor tyrosine kinases, like EGFR and ErbB2, are crucial in cancer. This review focuses on their role in breast and lung cancers and how targeting these pathways impacts treatment and resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • ErbB receptor tyrosine kinases are vital in normal physiology and cancer.
  • Epidermal growth factor receptor (EGFR) and ErbB2 are frequently altered in epithelial tumors, driving cancer development and progression.
  • These receptors activate multiple intracellular pathways, making them key targets for cancer therapies.

Purpose of the Study:

  • To review the role of ErbB receptors in breast tumors with ERBB2 amplification and non-small cell lung cancer (NSCLC) with EGFR mutations.
  • To discuss the significance of the PI3K/Akt pathway in cancer development and response to targeted therapies.
  • To explore mechanisms of resistance to ErbB-targeted therapeutics.

Main Methods:

  • Literature review focusing on ErbB signaling in specific cancer types.
  • Analysis of data on the PI3K/Akt pathway's involvement in oncogenesis and therapy response.
  • Examination of resistance mechanisms against ErbB-targeted drugs.

Main Results:

  • ErbB receptors, particularly EGFR and ErbB2, are implicated in the pathogenesis of various epithelial cancers.
  • The PI3K/Akt pathway is a critical mediator of both cancer development and response to targeted ErbB therapies.
  • Understanding resistance mechanisms is essential for improving therapeutic efficacy.

Conclusions:

  • Targeting ErbB receptors is a validated strategy in treating ERBB2-amplified breast cancer and EGFR-mutated NSCLC.
  • The PI3K/Akt pathway is a central player in ErbB-driven cancers and influences treatment outcomes.
  • Further research into resistance mechanisms is needed to overcome therapeutic limitations.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...